The human malaria- Aotus monkey model: a historical perspective in antimalarial chemotherapy research at the Gorgas Memorial Laboratory-Panama
- PMID: 38837364
- PMCID: PMC11232403
- DOI: 10.1128/aac.00338-24
The human malaria- Aotus monkey model: a historical perspective in antimalarial chemotherapy research at the Gorgas Memorial Laboratory-Panama
Abstract
The human malaria-Aotus monkey model has served the malaria research community since its inception in 1966 at the Gorgas Memorial Laboratory (GML) in Panama. Spanning over five decades, this model has been instrumental in evaluating the in vivo efficacy and pharmacokinetics of a wide array of candidate antimalarial drugs, whether used singly or in combination. The animal model could be infected with drug-resistant and susceptible Plasmodium falciparum and Plasmodium vivax strains that follow a characteristic and reproducible course of infection, remarkably like human untreated and treated infections. Over the years, the model has enabled the evaluation of several synthetic and semisynthetic endoperoxides, for instance, artelinic acid, artesunate, artemether, arteether, and artemisone. These compounds have been evaluated alone and in combination with long-acting partner drugs, commonly referred to as artemisinin-based combination therapies, which are recommended as first-line treatment against uncomplicated malaria. Further, the model has also supported the evaluation of the primaquine analog tafenoquine against blood stages of P. vivax, contributing to its progression to clinical trials and eventual approval. Besides, the P. falciparum/Aotus model at GML has also played a pivotal role in exploring the biology, immunology, and pathogenesis of malaria and in the characterization of drug-resistant P. falciparum and P. vivax strains. This minireview offers a historical overview of the most significant contributions made by the Panamanian owl monkey (Aotus lemurinus lemurinus) to malaria chemotherapy research.
Keywords: Aotus; Panama; Plasmodium falciparum; Plasmodium vivax; animal models; antimalarials; chemotherapy; history of medicine; malaria; non-human primates.
Conflict of interest statement
The author declares no conflict of interest.
Similar articles
-
UK malaria treatment guidelines 2016.J Infect. 2016 Jun;72(6):635-649. doi: 10.1016/j.jinf.2016.02.001. Epub 2016 Feb 12. J Infect. 2016. PMID: 26880088 Free PMC article.
-
In Vivo Efficacy and Pharmacokinetics of the 2-Aminomethylphenol Antimalarial JPC-3210 in the Aotus Monkey-Human Malaria Model.Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01538-19. doi: 10.1128/AAC.01538-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31843994 Free PMC article.
-
Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.Malar J. 2019 Jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2. Malar J. 2019. PMID: 30654808 Free PMC article.
-
The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria.PLoS Negl Trop Dis. 2011 Dec;5(12):e1325. doi: 10.1371/journal.pntd.0001325. Epub 2011 Dec 27. PLoS Negl Trop Dis. 2011. PMID: 22216359 Free PMC article. Review.
-
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.Southeast Asian J Trop Med Public Health. 2013;44 Suppl 1:201-30; discussion 306-7. Southeast Asian J Trop Med Public Health. 2013. PMID: 24159833 Review.
Cited by
-
The Owl Monkey (Aotus spp.) as an Animal Research Model. Part 3: Research Use and Diseases.J Med Primatol. 2025 Jun;54(3):e70024. doi: 10.1111/jmp.70024. J Med Primatol. 2025. PMID: 40396699 Review.
References
-
- WHO . 2023. World malaria report 2023. WHO
-
- WHO . 2015. World malaria report 2015. WHO, Geneva, Switzerland.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources